American journal of hematology · 2009
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McGregor Bradley A, Brown Alexander W, Osswald Michael B, Savona Michael R
Аннотация
The standard dose of clofarabine is 52 mg/m2 for pediatrics and 40 mg/m2 in adults. Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT. All patients had a significant response to therapy. Published pharmacokinetic analysis revealed no difference in peak plasma or intracellular concentrations at clofarabine dosed above 40 mg/m2, yet inhibition of replication in leukemia cells was only sustained over 24 hr at 55 mg/m2. Despite this, there have been no reports of high dose clofarabine used in this setting. Our experience implies that there may be a niche role for clofarabine in reducing disease burden before allo-HSCT for adults with relapsed ALL.
Предметные рубрики MeSH
Adenine NucleotidesAdultAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsArabinonucleosidesClinical Trials as TopicClofarabineCombined Modality TherapyCyclophosphamideCytarabineDexamethasoneDose-Response Relationship, DrugDoxorubicinDrug EvaluationEtoposideFatal OutcomeFilgrastimGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHumansIdarubicinMaleMitoxantronePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaRecombinant ProteinsRecurrenceRemission InductionReoperationSalvage TherapyVidarabineVincristineYoung Adult